Minimally Invasive Lung Cancer Surgery (VATS) Prolongs Survival Compared With Open Lobectomy

📅 Date and Significance of the Event

IASLC World Conference on Lung Cancer 2025 (WCLC 2025)featured a meta-analysis of randomized trials showing that, in early-stage non-small cell lung cancer (NSCLC), lobectomy using video-assisted thoracoscopic surgery (VATS) was associated with a 21% reduction in the risk of death compared with open lobectomy in patients.

This is the first trial-level evidence, with a high level of certainty, showing that the access technique affects not only comfort and recovery time, but also overall survival in this setting. (Conference date and location: September 6–9, 2025, Barcelona).

🧪 Methods — Why Is This a Reliable Study?

This analysis is a meta-analysis designed to achieve a high level of evidence by examining only randomized controlled trials (RCTs) . Most earlier studies were observational and at risk of selection bias, making this meta-analysis design important for clearly establishing the true difference between surgical techniques.

• Literature search: A comprehensive search of international databases (PubMed, Embase, etc.) reviewed 556 studies. Only 3 randomized trials met the criteria.
• Trials:
  • Bendixen et al. – Denmark, Lancet Oncology, NCT01278888
  • Long et al. – China, NCT01102517
  • Lim et al. – United Kingdom, NCT03521375
• Number of patients: A total of 1,185 patients (VATS: 586, Open Lobectomy: 599)
• Data analysis: Individual data were collected for each patient, and the Cochrane risk-of-bias tool was used for quality assessment. Bias risk was low, and groups were balanced except for age.
• Analytical approach: All analyses followed the intention-to-treat principle, including subgroup analyses and sensitivity analyses in the assessment.

📊 Findings — Key Numbers

Subgroup analysis showed no difference in effect by age (OS p=0.83; DFS p=0.43).

🌐 What Do International Guidelines Say?

• NCCN (2025 Patient Guidelines): The curative approach in early-stage disease is surgical resection; when technically feasible, minimally invasive approaches are preferred (lobectomy, or segmentectomy in suitable cases).
• CHEST (July 2025 guideline): In clinical stage I NSCLC, a minimally invasive approach rather than thoracotomy is recommended. Adjuvant treatment recommendations after resection in stage II are detailed.
• ESMO (2025 CPG): Surgery is standard in early and locally advanced NSCLC; with appropriate center and surgeon experience, minimally invasive lobectomy/segmentectomy is widely adopted.

Clinical Practice — Which Method Is Used More Often?

In recent years, US and European databases have shown that the proportion of minimally invasive resections (VATS/RATS) has increased substantially; open surgery rates are declining at many high-volume centers. STS and national audit reports describe wider use of minimally invasive platforms and conversion rates falling to single digits.

• Perioperative quality: VATS, is superior to open surgery for postoperative pain and quality of life (Bendixen RCT, Lancet Oncology).
• Cost-effectiveness: In stage I, VATS is cost-effective, with higher QALYs and lower total costs for treatment.

Clinical Messages — What Should Be Done in Practice?

1. If technically feasible, plan VATS as the primary approach ; do not compromise oncological principles (complete lymph node dissection, negative margins).
2. Patient selection and center experience are critical: maintain a low threshold for conversion to open surgery for difficult tumor locations, advanced nodal disease, dense adhesions or limited experience.
3. Perioperative benefits (pain, complications, discharge) and the OS advantage (HR 0.79) should be clearly explained during patient counseling.
4. Robotic vs VATS: Current comparisons suggest similar safety and outcomes ; choice should depend on institutional infrastructure and team expertise.

❓ Frequently Asked Questions

Is Oncological Dissection Equivalent With VATS? The meta-analysis showed no DFS difference (HR 0.91), suggesting oncological equivalence.

Is Every Patient a VATS Candidate? No. Tumor anatomy, nodal status, previous surgery and technical difficulties require case-by-case decisions, with safe conversion when needed.

📚 References

• ASCO Post – VATS vs Open, 21% reduction in OS (WCLC 2025, PL03.13).
• IASLC WCLC 2025 — Barcelona, September 6–9, 2025.
• EurekAlert — VATS meta-analysis press release; ecancer — news.
• NCCN Early-Stage Lung Cancer (2025, Patient Guidelines).
• CHEST 2025 Guideline — Early-Stage NSCLC.